Abstract
Elvitegravir/cobicistat/emtricitabine/tenofovirDF (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitor recently approved as antiretroviral treatment. In this paper we analysed its use and advantages in naïve and experienced HIV-infected patients and we focused on special populations in which EVG/COBI/FTC/TDF could be a suitable option. Furthermore the manuscript reports the recent patent of EVG which may have an influence on the management of HIV-infected patients in the next future.
MeSH terms
-
Adenine / analogs & derivatives*
-
Adenine / therapeutic use
-
Anti-HIV Agents / therapeutic use*
-
Carbamates / therapeutic use*
-
Cobicistat
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Drug Combinations
-
Emtricitabine
-
HIV Infections / drug therapy*
-
HIV-1 / drug effects
-
Humans
-
Patents as Topic
-
Phosphorous Acids / therapeutic use*
-
Quinolones / therapeutic use*
-
Thiazoles / therapeutic use*
Substances
-
9-(2-((bis(pivaloyloxymethoxy)phosphinoyl)methoxy)propyl)adenine
-
Anti-HIV Agents
-
Carbamates
-
Drug Combinations
-
Phosphorous Acids
-
Quinolones
-
Thiazoles
-
Deoxycytidine
-
elvitegravir
-
Emtricitabine
-
Adenine
-
Cobicistat